Summary
COVID-19 is an infectious disease that spreads worldwide, can progress
rapidly, affect individuals of all ages, and cause death, especially in
the elderly and people with chronic diseases. It has predisposed a
relatively high number of patients to acute respiratory distress
syndrome, and co-infections are a frequent complication, especially
during prolonged hospital stays. Bacterial or viral co-infections with
SARS-CoV-2 have been reported in many studies, but knowledge of
Aspergillus co-infection in patients with COVID-19 is limited.
This study presents a 57-year-old male patient with COVID-19 who had had
no lung disease before COVID-19 pneumonia. However, after COVID-19
pneumonia with sequels and treatments that include corticosteroids and
IL-6 receptor antagonists, an invasive pulmonary aspergillus (IPA)
cavity occurred immediately.
In addition to the fact that COVID-19 infection progresses with
destructive parenchymal damage and sequelae, the effectiveness of
treatment is limited, and treatment-related side effects and
complications can be examined. Therefore, clinical and radiological
follow-up of patients whose symptoms persist after infection is
essential.